Amped-up_van⚡

⚜️Diligere, Sapere, Audere, Fidare ⚜️ 🔬🩺 ☢️

[Amped-up_van⚡ @Rhyll2601]

Me: In my life, 2 persons pa lang gyud akoa gi love deeply

Friend; Ha? Sa kadaghan nimong gi kiss, duha ra gyud?

🤣🤣🤣

[Amped-up_van⚡ @Rhyll2601]

The best indicator of a lasting bond isn't how little you fight, but how well you repair.

[MV Chandrakanth @ChandrakanthMv]

• Two bone drugs
• Two different rules
• Zoledronic = treat through
• Denosumab = Month-5 window + restart
Why? The biology is not the same.
#Oncology #Dentistry #MRONJ #MedEd

[Dr Rishabh Jain @DrRishabhOnco]

Decades later, R-CHOP still rules DLBCL 👑
Not by luck. By design.

This regimen survives because it follows biological warfare principles, not trial-and-error.

🧠 Two rules it obeys
Spatial cooperation → different targets
Temporal cooperation → different cell phases

🎯 Rituximab marks the enemy
CD20 tagging turns the immune system into a guided missile and primes cells for chemo kill.

🔨 Cyclophosphamide + Doxorubicin crush DNA
Crosslinking plus Topo-II damage. Cell-cycle independent. No escape route.

❄️ Vincristine freezes division
Microtubules locked. The cell reaches mitosis and dies trying.

☠️ Prednisone finishes the job
Direct lympholysis. Not supportive care. Active cytotoxicity.

Maximum kill. Minimal overlap.
That’s why R-CHOP endures. 🧪

#Oncology #MedTwitter #Lymphoma #Hematology #MedEd

@ASCO @ESMO_Open @myESMO @ASCO

[Dr Rishabh Jain @DrRishabhOnco]

Every January, oncologists promise the same thing.
“I’ll read trials more carefully this year.”

Then we read the abstract conclusion and move on.

Here’s the uncomfortable truth:
📣 Abstracts sell drugs.
📊 Data tells the truth.

Let me show you how to autopsy a Phase III oncology trial quickly 🧵👇

#Oncology #MedEd #MedTwitter
@OncoAlert @myESMO @ESMO_Open @ASCO

[MV Chandrakanth @ChandrakanthMv]

𝐃𝐅𝐒, 𝐏𝐅𝐒, 𝐄𝐅𝐒 — 𝐬𝐚𝐦𝐞 𝐥𝐞𝐭𝐭𝐞𝐫𝐬. 𝐕𝐞𝐫𝐲 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬.

🔹 𝐃𝐅𝐒: Did the disease come back?
🔹 𝐏𝐅𝐒: Did the disease grow?
🔹 𝐄𝐅𝐒: Did anything go wrong?
Endpoints matter.
𝐂𝐨𝐧𝐭𝐞𝐱𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬 𝐦𝐨𝐫𝐞. 🧠

#Oncology #ClinicalTrials
#EvidenceBasedMedicine #MVOnco

[Arky @arkcarlly]

Basta this year, being selective about who gets access to your precious time and energy is a form of self-care.

[Dr Rishabh Jain @DrRishabhOnco]

Radical cystectomy is NOT the only standard for MIBC anymore. 🚻🔥

The International Bladder Cancer Group just made it crystal clear in European Urology 📘

If you remember ONE thing, remember this 👇

🧠 TMT = TURBT + RT + Chemo

That’s bladder preservation.
That’s guideline backed.
That’s no longer niche care.

Who wins with TMT 🎯
🟢 Single tumor
🟢 cT2
🟢 No hydronephrosis
🟢 No multifocal CIS
🟢 Good bladder function

Big myth busted ⚠️
cT3–4, CIS, hydronephrosis
👉 Worse prognosis ≠ absolute no

The safety net that makes this work 🛟
If local failure happens
👉 Early salvage cystectomy still cures

What is NOT routine 🚫
❌ Partial cystectomy for most
❌ Radical TUR alone
❌ Skipping local therapy after chemo or IO outside trials

One line takeaway 💡
If you never discuss TMT, you are denying patients a real option.

Would you offer TMT to every eligible MIBC patient ❓

📖 Full paper in comment ⬇️

#BladderCancer #UroOncology #OncoTwitter #MedTwitter #EAU

@OncoAlert @myESMO @ESMO_Open @Uromigos

[Words @itswords_]

1st of January ✨

[Amped-up_van⚡ @Rhyll2601]

Red flag kaayo nang DARVO pattern ang reply. 🚩🚩🚩

[Amped-up_van⚡ @Rhyll2601]

Allowing better things and better relationships to flow in.

[Amped-up_van⚡ @Rhyll2601]

See you when our paths and timelines will align. Like fireworks it was beautiful while it lasted.

[♡ @astralbaes]

could be us

[Amped-up_van⚡ @Rhyll2601]

@Tarotbeing 333

[Arky @arkcarlly]

Basta, when people don’t consider you in the same way you consider them, let them go. There’re actually so many people in the world that can match your energy and love you the way you love.

[Amped-up_van⚡ @Rhyll2601]

@insidemanifest 333

[Dr sthanu subramanian @drsthanus]

A diagnostic and treatment algorithm for Malignancy of unknown origin, also known as cancer of unknown primary (CUP).

https://t.co/BxUFnfb4Uw

[Dr Rishabh Jain @DrRishabhOnco]

⚖️ TNT in Rectal Cancer: Promise or Premature?

💊 Total Neoadjuvant Therapy (TNT) has been hyped for LARC, but does it really beat standard chemoradiation (CRT)?

👥 4 Key RCTs:

•RAPIDO → ↓ distant mets, ❌ no OS gain

•PRODIGE-23 → ↑ DFS, small OS edge (but early curve drop & underpowered)

•POLISH II → initial OS benefit → vanished at 8 yrs

•STELLAR → ↑ 3-yr OS (86.5% vs 75.1%), but short f/u

📊 pCR rates: higher with TNT (22.5% vs 13.3%) but confounded by shorter CRT–surgery interval.

🚨 Takeaway: TNT = modest ↓ distant mets, unclear OS benefit, more toxicity. CRT remains standard until better biomarkers guide who truly benefits.

📖Ubink et al. JCO Oncol Pract. 2025.

DOI: https://t.co/OQSE3RPRPj

#OncoTwitter #ColorectalCancer #RadiationOncology #Oncology
@OncoAlert @esmo_open @myESMO @ASCO @JCOOPjournal

[Amped-up_van⚡ @Rhyll2601]

There are moments when presence is not a luxury — it’s a responsibility for anyone who claims to care.